What's breaking now, across thousands of outlets.
Futures on the Dow were significantly worse than the S&P 500 because of a cardiovascular drug’s late-stage setback.
We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.
Guy Johnson, Tom Mackenzie and Adam Linton break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade." (Source: Bloomberg)
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
The specialist health economics modeling and analytics business joins Initiate's market access and HEOR platform. The post QPE’s Initiate completes add-on acquisition of Dark Peak Analytics appeared…
More than 60% of cryptocurrency platforms that lost money due to cyberattacks had undergone independent security audits, CoinGecko said.
